---
# Documentation: https://wowchemy.com/docs/managing-content/

title: Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant
  Drug in COVID-19
subtitle: ''
summary: ''
authors:
- Barbara Malinowska
- Marta Baranowska-Kuczko
- Aleksandra Kicman
- Eberhard Schlicker
tags:
- '"COVID-19"'
- '"SARS-CoV-2"'
- '"ACE2"'
- '"cannabidiol"'
- '"respiratory disease"'
categories: []
date: '2021-01-01'
lastmod: 2021-03-08T10:12:43+01:00
featured: false
draft: false

# Featured image
# To use, add an image named `featured.jpg/png` to your page's folder.
# Focal points: Smart, Center, TopLeft, Top, TopRight, Left, Right, BottomLeft, Bottom, BottomRight.
image:
  caption: ''
  focal_point: ''
  preview_only: false

# Projects (optional).
#   Associate this post with one or more of your projects.
#   Simply enter your project's folder or file name without extension.
#   E.g. `projects = ["internal-project"]` references `content/project/deep-learning/index.md`.
#   Otherwise, set `projects = []`.
projects: []
publishDate: '2021-05-26T09:24:27.710022Z'
publication_types:
- '2'
abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may
  lead to coronavirus disease 2019 (COVID-19) which, in turn, may be associated with
  multiple organ dysfunction. In this review, we present advantages and disadvantages
  of cannabidiol (CBD), a non-intoxicating phytocannabinoid from the cannabis plant,
  as a potential agent for the treatment of COVID-19. CBD has been shown to downregulate
  proteins responsible for viral entry and to inhibit SARS-CoV-2 replication. Preclinical
  studies have demonstrated its effectiveness against diseases of the respiratory
  system as well as its cardioprotective, nephroprotective, hepatoprotective, neuroprotective
  and anti-convulsant properties, that is, effects that may be beneficial for COVID-19.
  Only the latter two properties have been demonstrated in clinical studies, which
  also revealed anxiolytic and antinociceptive effects of CBD (given alone or together
  with Î”9-tetrahydrocannabinol), which may be important for an adjuvant treatment
  to improve the quality of life in patients with COVID-19 and to limit post-traumatic
  stress symptoms. However, one should be aware of side effects of CBD (which are
  rarely serious), drug interactions (also extending to drugs acting against COVID-19)
  and the proper route of its administration (vaping may be dangerous). Clearly, further
  clinical studies are necessary to prove the suitability of CBD for the treatment
  of COVID-19.
publication: '*International Journal of Molecular Sciences*'
url_pdf: https://www.mdpi.com/1422-0067/22/4/1986
doi: 10.3390/ijms22041986
---
